Wei Hua, MSc, MHS, MD, PhD

Deputy Division Director
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA

Poster(s):

• (119) Performance of the US Food and Drug Administration’s COVID-19 Disease Severity Categorization for Use in Real-World Data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (234) Analysis of Medicinal Product Utilization Data in the FDA Sentinel System to Inform the Development of a Pregnancy Safety Study Framework
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (235) Analysis of Postapproval Pregnancy Safety Studies Associated with FDA Approved Products
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (288) Patterns of Prescribed and Dispensed Medicines among Non-Hospitalized Pregnant women with COVID-19: a Prospective Meta-analysis pooling findings from Healthcare Databases in Europe and North America
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (305) Prevalence of Selected Health Conditions among Individuals with Childbearing Potential to Inform the Development of the Pregnancy Safety Study Framework
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (312) Sources and Characteristics of Quantitative Human Pregnancy Safety Data in U.S. FDA Approved Product Labeling, 2015-2021
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (ASPOT01) Validity of the ICD-10-CM diagnosis code to identify patients with COVID-19 in Medicare administrative claims data
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST